MX2016010599A - Analogos de glucagon estables y uso para el tratamiento de hipoglucemia. - Google Patents

Analogos de glucagon estables y uso para el tratamiento de hipoglucemia.

Info

Publication number
MX2016010599A
MX2016010599A MX2016010599A MX2016010599A MX2016010599A MX 2016010599 A MX2016010599 A MX 2016010599A MX 2016010599 A MX2016010599 A MX 2016010599A MX 2016010599 A MX2016010599 A MX 2016010599A MX 2016010599 A MX2016010599 A MX 2016010599A
Authority
MX
Mexico
Prior art keywords
hypoglycaemia
treatment
glucagon analogues
stable glucagon
stable
Prior art date
Application number
MX2016010599A
Other languages
English (en)
Inventor
F Lau Jesper
Kruse Thomas
Kresten Nielsen Peter
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2016010599A publication Critical patent/MX2016010599A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a derivados de análogos de glucagón, que comprenden las sustituciones Imp1 y His3, un sustituyente que tiene de tres a diez porciones negativamente cargadas unidas covalentemente a una cadena lateral de una lisina, así como compuestos intermedios y composiciones de los mismos y su uso en medicina.
MX2016010599A 2014-02-18 2015-02-18 Analogos de glucagon estables y uso para el tratamiento de hipoglucemia. MX2016010599A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14155497 2014-02-18
PCT/EP2015/053394 WO2015124612A1 (en) 2014-02-18 2015-02-18 Stable glucagon analogues and use for treatment of hypoglycaemia

Publications (1)

Publication Number Publication Date
MX2016010599A true MX2016010599A (es) 2016-11-18

Family

ID=50112828

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010599A MX2016010599A (es) 2014-02-18 2015-02-18 Analogos de glucagon estables y uso para el tratamiento de hipoglucemia.

Country Status (15)

Country Link
US (1) US9963496B2 (es)
EP (1) EP3107560A1 (es)
JP (1) JP2017509603A (es)
KR (1) KR20160114082A (es)
CN (1) CN106029088A (es)
AR (1) AR100306A1 (es)
AU (1) AU2015220909A1 (es)
BR (1) BR112016016321A2 (es)
CA (1) CA2939763A1 (es)
IL (1) IL246483A0 (es)
MX (1) MX2016010599A (es)
RU (1) RU2016134425A (es)
SA (1) SA516371639B1 (es)
TW (1) TW201613955A (es)
WO (1) WO2015124612A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
KR102184241B1 (ko) 2012-05-03 2020-12-01 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법
CN104662038B (zh) 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
KR102569036B1 (ko) 2013-10-17 2023-08-23 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
CN105849122B (zh) 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
CN107108713A (zh) 2014-10-10 2017-08-29 诺和诺德股份有限公司 稳定的基于glp‑1的glp‑1/胰高血糖素受体共激动剂
RU2716985C2 (ru) 2014-10-29 2020-03-17 Зилэнд Фарма А/С Соединения-агонисты gip и способы
RU2735762C2 (ru) 2015-04-16 2020-11-06 Зилэнд Фарма А/С Ацилированный аналог глюкагона, его применение и способы получения
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
NZ541365A (en) 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
RU2007134155A (ru) 2005-03-18 2009-04-27 Ново Нордиск А/С (DK) Glp-1 соединения с увеличенным временем полужизни
EP1959986B1 (en) 2005-11-07 2014-07-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
SG177953A1 (en) 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
BRPI0807728A2 (pt) 2007-02-15 2012-04-17 Univ Indiana Res & Tech Corp co-agonistas de receptor glucagon/glp-1
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP6108659B2 (ja) 2008-06-17 2017-04-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト
CN102088989B (zh) 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
WO2010096052A1 (en) * 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
DK2454282T3 (en) * 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
CA2792663A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
CN103596583B (zh) * 2011-03-28 2016-07-27 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
EP2718317B1 (en) 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
IN2014CN02448A (es) 2011-09-23 2015-06-19 Novo Nordisk As
US10000542B2 (en) * 2012-05-08 2018-06-19 Novo Nordisk A/S Double-acylated GLP-1 derivatives
JP6311708B2 (ja) * 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇｉｐ受容体活性を示すグルカゴンアナローグ

Also Published As

Publication number Publication date
EP3107560A1 (en) 2016-12-28
CA2939763A1 (en) 2015-08-27
US9963496B2 (en) 2018-05-08
CN106029088A (zh) 2016-10-12
AR100306A1 (es) 2016-09-28
WO2015124612A1 (en) 2015-08-27
TW201613955A (en) 2016-04-16
AU2015220909A1 (en) 2016-07-14
KR20160114082A (ko) 2016-10-04
JP2017509603A (ja) 2017-04-06
BR112016016321A2 (pt) 2017-10-03
RU2016134425A (ru) 2018-03-20
RU2016134425A3 (es) 2018-12-10
IL246483A0 (en) 2016-08-31
US20170008943A1 (en) 2017-01-12
SA516371639B1 (ar) 2018-10-25

Similar Documents

Publication Publication Date Title
SA516371639B1 (ar) نظائر جلوكاجون مستقرة واستخدامها في علاج نقص السكر بالدم
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016501702B1 (en) Pyrazole amide derivative
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
RS61137B1 (sr) A22k, desb27, b29r, des b30, na epsilon poziciji lizina 22 acilovanog analoga humanog insulina
UA118610C2 (uk) Спіроциклічні інгібітори катепсину c
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MY181641A (en) Amino pyran ring derivative and composition and use thereof
EP3185862A4 (en) PROTECTIVE METALOTHION ANALOG COMPOUNDS, THEIR COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF PATHOGENIC DISEASES
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2017009608A (es) Compuestos anticancerigenos.
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
GB2546703A (en) Compounds
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.